Aurinia Pharmaceuticals Inc. AUPH 深 沪
等待开盘 10-14 09:30:00 美东时间
16.36
-0.190
-1.15%
华盛通- 最 高16.58
- 今 开16.46
- 成交量 113.77万股
- 最 低 16.21
- 昨 收 16.55
- 总市值 21.77亿
- 52周最高 19.25
- 市盈率 静 7.90
- 换手率 0.00%
- 52周最低 11.885
- 委 比 -31.41%
- 总股本 1.33亿
- 历史最高 33.972
- 量 比 1.53
- 振 幅 2.24%
- 历史最低 1.41
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多LB Pharmaceuticals appoints Joseph Miller as CFO
LB Pharmaceuticals (LBRX) announced on Thursday the appointment of Joseph Miller as chief financial officer, or CFO. Before joining LB Pharmaceuticals, Miller served as CFO of Aurinia Pharmaceuticals....
09-03 20:37
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
LB Pharmaceuticals has appointed Joseph Miller as its Chief Financial Officer. With over 20 years of experience in biopharmaceutical finance, Miller brings expertise in financial strategy, operations, and organizational growth. His appointment coincides with the company's pivotal NOVA-2 clinical trial for LB-102, a potential schizophrenia treatment. Miller's leadership at Aurinia Pharmaceuticals and Avalo Therapeutics, where he successfully scale...
09-03 12:00
Aurinia settles Lupkynis patent litigation with Teva
Teva Pharmaceutical Industries (TEVA) will not be able to launch a generic version of Aurinia Pharmaceuticals' (AUPH) Lupkynis (voclosporin) until Dec. 7, 2036, at the earliest under a settlement. Tev...
08-20 05:12
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva Pharmaceuticals Inc. ("Teva") to resolve patent infringement litigation relating to Teva’s filing of an Abbre...
08-20 04:07
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $323.065 million estimate.
08-06 20:41
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.24 by 16.67 percent. This is a 75 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $83.220 mil...
08-06 20:40
Aurinia Targets Myasthenia Gravis With New Aritinercept Trial, Expanding Its Growth Story
Aurinia Pharmaceuticals ($AUPH) announced an update on their ongoing clinical s...
08-04 00:32
Zacks行业展望：Indivior、Aurinia、Ironwood、Altimmune及Marker
2026年6月26日，扎克斯股票研究聚焦5只小型制药标的：Indivior制药（INDV）、Aurinia制药（AUPH）、Ironwood制药（IRWD）、...
06-26 18:07
Aurinia’s PRESERVE Trial: New Combination Strategy for Lupus Nephritis in Focus
Aurinia Pharmaceuticals ($AUPH) announced an update on their ongoing clinical s...
06-13 00:34
